Project 2: Muscular dystrophy clinical trial foundations. Substantial evidence implicates aberrant reactivation of DUX4 expression as the cause of facioscapulohumeral dystrophy (FSHD). Expression profiling of primary myoblasts transduced with DUX4 has identified DUX4 regulated genes, many of which are involved in germline and early stem cell development. Many of these genes are expressed in FSHD muscle but not in muscle from healthy controls, making them ideal biomarker candidates. As FSHD research enters a translational phase, the development of mechanistic, prognostic, and diagnostic biomarkers becomes critical in moving the translational process forward.
Aim 1 is a cooperative clinical study for biomarker evaluation in FSHD that will (a) develop FSHD patient registration, assessments, and sample collection in Seattle that parallel those developed in Rochester;(b) develop FSHD MRI assessment capabilities in Rochester that parallel those developed in Seattle;and (c) perform a focused collaborative clinical study to determine the molecular determinants of the MRI findings characteristic of FSHD and to prioritize the best candidate biomarkers for disease activity.
Aim 2 will determine whether CD8+ T cells infiltrating FSHD muscle recognize DUX4 induced cancer/testes (C/T) antigens, and will (a) characterize the phenotype, location, and cytokine profile of the T cell/immune cell infiltrate in skeletal muscle in FSHD;(b) expand T cells from FSHD muscle, determine the T cell receptor Vb gene usage and characterize their function;and (c) determine whether T cells derived from FSHD muscle recognize FSHD muscle antigens. These combined aims represent a synergistic effort to evaluate the relationship between tissue biomarkers, histopathology, MRI imaging characteristics, and muscle function, together with a direct characterization of the T cell infiltrate the immune response in the pathophysiology of FSHD.

Public Health Relevance

This project relates to the broad scope of the Center because it develops the clinical infrastructure necessary for future gene therapy trials in Duchenne and FSHD dystrophies at the University of Washington, and for future inter-institutional trials in muscular dystrophies. In addition it provides a rich translational clinical research program for the Investigator Development and Patient Outreach Core and it uses vectors produced by the Scientific Research Resource Core

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
United States
Zip Code